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GIP: An Inconsequential Incretin or Not?
T
he “incretin effect” refers to the en-
hancement of insulin secretion in
response to an oral glucose load rel-
ativetothatofanisoglycemicintravenous
glucose challenge (1). In humans, the in-
cretin effect is mediated by two peptide
hormones, glucagon-like peptide 1
(GLP-1)andglucose-dependentinsulino-
tropic polypeptide (GIP), which are se-
creted from enteroendocrine cells in
response to nutrients entering the gut.
GLP-1 secretion from L-cells, found in
highestdensityinthedistalileumbutalso
throughout the small and large intestine,
isstimulatedbyglucose,aminoacids,and
fat. GIP, in contrast, is produced by the
K-cells in the proximal duodenum; its se-
cretion is also stimulated by glucose, but
is particularly enhanced by fat (2). Both
GLP-1 and GIP are derived from prohor-
mones (proglucagon and pro-GIP, re-
spectively) and secreted as active
hormones. The effects of both GLP-1 and
GIP are mediated by speciﬁc G protein–
coupled receptors present on the plasma
membrane of -cells and other target tis-
sues. GLP-1 and GIP increase insulin se-
cretion from -cells in a glucose-
dependent manner. In rodents, GLP-1
and GIP also enhance -cell mass by in-
creasing rates of proliferation and de-
creasing rates of apoptosis. Many
physiological effects of GLP-1 and GIP do
not overlap, however. GLP-1 suppresses
glucagon secretion, slows gastric empty-
ing, and has central nervous system ef-
fects to regulate appetite, whereas GIP
does not. GIP, on the other hand, has di-
rect effects on adipocytes to promote tri-
glyceridestorage(1).Theincretinsystem,
therefore,facilitatesintegratedphysiolog-
ical responses to meals of different size
and composition allowing ingested nutri-
ents to be optimally metabolized.
Theincretineffectisanimportantde-
terminantofglucosetolerance.Inpatients
with type 2 diabetes, the incretin effect is
markedly diminished and is less than half
thatobservedinsubjectswithnormalglu-
cosetolerance(NGT)(3).Thisdefectdoes
not appear to be due to impairments in
incretinhormonesecretion,becausemost
studies have found comparable circulat-
ing concentrations of GLP-1 and GIP in
response to nutrient challenges in sub-
jectswithtype2diabetesandnondiabetic
control subjects (4). Rather, it appears
that -cell insulin secretory responses to
incretin hormones are impaired in pa-
tients with type 2 diabetes. With GLP-1
thisdefectismodestandcanbeovercome
with infusions that achieve higher GLP-1
levels. In contrast, even infusions that
achieve supraphysiological GIP concen-
trations fail to elicit a signiﬁcant insulin
secretory response in patients with type 2
diabetes (5). Thus, GLP-1 infusions
quickly normalize blood glucose levels in
patients with type 2 diabetes, whereas
GIP infusions do not (6). These observa-
tions created considerable enthusiasm for
the development of pharmaceutical
agentsforthetreatmentoftype2diabetes
that work through the incretin axis, and
particularly for those that enhance GLP-1
activity. Unfortunately, native GLP-1 is
not suitable as a therapy for the treatment
oftype2diabetesbecauseofitsshorthalf-
life. In circulation, both GLP-1 and GIP
are rapidly inactivated by dipeptidylpep-
tidase-4(DPP-4),aubiquitousserinepro-
tease that cleaves the two NH2-terminal
amino acids from active hormones ren-
deringtheminactive.Asaconsequenceof
the action of DPP-4 as well as rapid clear-
ancebythekidneys,thehalf-lifeofGLP-1
in circulation is 1–2 min and that of GIP
around7min.Twoapproacheshavebeen
successfully employed to enhance the in-
cretin effect. The ﬁrst approach, inject-
able GLP-1 agonists that are resistant to
DPP-4, is exempliﬁed by exenatide and
the recently approved human GLP-1 an-
alog liraglutide. The second approach,
orallyavailable,smallmoleculeinhibitors
of DPP-4, includes the approved agents
sitagliptin and saxagliptin as well as sev-
eral other agents in development (7). Un-
like GLP-1 agonists, DPP-4 inhibitors
increase active levels of both GLP-1 and
GIP. Because studies indicate GIP has
minimaleffectsintype2diabetes,mostof
the therapeutic beneﬁt of this class has
been ascribed to the actions of GLP-1.
Consequently, little attention has been
paid to the physiology and pharmacolog-
icalpotentialofGIP,eventhoughthiswas
the ﬁrst incretin hormone identiﬁed.
In this issue of Diabetes Care, So-
lomon et al. (8) examines the contribu-
tions of GIP to changes in insulin
secretion following a lifestyle interven-
tion. A total of 29 older obese men and
womenwitheitherNGT(n16)ornew-
ly-diagnosed type 2 diabetes (n  13)
participated in a 3-month weight loss and
exercise intervention. At baseline and af-
ter the intervention, oral glucose toler-
ance tests were performed to measure
nutrient-induced insulin secretion and
GIP responses and hyperinsulinemic-
euglycemic glucose clamps were per-
formed to measure insulin action. They
observed that the lifestyle intervention,
which decreased body weight by around
5kgandincreasedVO2maxinbothgroups,
signiﬁcantly improved glucose tolerance
inthetype2diabetesgroupbutnotinthe
NGT group. Insulin action increased by
46% in the NGT group, but signiﬁ-
cantly less so (26%) in the type 2 dia-
betic group. Insulin secretion decreased
in the NGT group in proportion to their
improvement in insulin action, but in-
creased in the type 2 diabetes group in
contrast. Similarly, incremental GIP re-
sponses to the glucose challenge in-
creased signiﬁcantly in those with type 2
diabetes, and tended to go down in those
with NGT. In the group as a whole,
changes in GIP were highly correlated to
changes in insulin secretion corrected for
the degree of insulin resistance following
the intervention. A similar relation be-
tween insulin secretion and GIP was pre-
viously reported in subjects with
impaired glucose tolerance by this group
of investigators, although in this earlier
studyinsulinactionwasnotdirectlymea-
sured (9). These results suggest that im-
proved -cell–compensatory responses
to insulin resistance following a lifestyle
interventionare,atleastinpart,mediated
by enhanced GIP secretion and action.
What is not clear from this study or
the group’s earlier work is whether the
enhanced insulin secretion with the life-
style intervention can be directly attrib-
uted to GIP, because insulin secretory
responses to GIP were not directly mea-
sured. Thus, it is possible that a common
mechanism altered by the lifestyle inter-
vention could account for parallel im-
provements in insulin and GIP secretion,
without there necessarily being a direct
link between the two processes. Never-
theless, other recent data support the no-
tion that incretin responses to GIP could
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ample, a recent study by Højberg et al.
(10) demonstrated that 4 weeks of inten-
sive insulin treatment markedly im-
proved insulin secretory responses to
infused GIP in patients with poorly con-
trolled type 2 diabetes. Interestingly, the
same intervention did not increase GIP
secretion, but did improve insulin secre-
tory responses to a standard mixed meal
in patients with type 2 diabetes, consis-
tent with an enhancement in incretin ac-
tion (11). It has been known for some
time that expression of the GIP receptor
on pancreatic -cells is downregulate by
hyperglycemia. Thus, the enhanced in-
cretin response to GIP following normal-
ization of glucose levels in the study by
Højberg et al. could be due to up-
regulation of the GIP receptor on the
-cells of these individuals. New insights
into the mechanisms by which this might
occur have recently been reported by
Gupta et al. (12) in preclinical models of
diabetes. This group observed that the
GIP receptor contains a functional perox-
isome proliferator–activated receptor-
(PPAR-) response element in the pro-
moter region of the gene. Interventions
thatdecreasedorincreasedPPAR-activ-
ity (including exposure to a thiazo-
lidinedione) resulted in corresponding
changes in GIP receptor expression. Col-
lectively, these data and the results of the
present study suggest that it is possible to
normalize the incretin effect in type 2 di-
abetes through interventions that de-
crease hyperglycemia, improve insulin
resistance, or both. Whether treating pa-
tients with type 2 diabetes with a thiazol-
idinedione will enhance incretin effects
mediated by GIP is not known, but is an
intriguing possibility given that thiazol-
idinedionesandDPP-4inhibitorsarenow
being studied in combination for the
treatment of type 2 diabetes. Could an
enhanced incretin effect contribute to the
durable effect of thiazolidinedione drugs?
We don’t know, but GIP may not be the
inconsequential incretin hormone in type
2 diabetes we thought it was after all.
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